This inventor holds 3 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignees: Cognition Pharmaceuticals LLC, Sention, Inc.. Active years: 2004-2009.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2004-2009
Title: The Innovations of Kjesten A Wiig
Introduction
Kjesten A Wiig is a notable inventor based in Providence, RI. He has made significant contributions to the field of cognitive health, particularly in relation to Multiple Sclerosis. With a total of 3 patents, his work focuses on innovative methods for treating cognitive impairments.
Latest Patents
Wiig's latest patents include groundbreaking methods for treating cognitive impairment in humans with Multiple Sclerosis. One of his notable inventions involves the use of an amphetamine compound to improve cognition. In one embodiment, the method includes administering an l-amphetamine compound, while in another, it involves administering an l-methamphetamine compound. Additionally, he has developed methods for treating impairments in memory consolidation, also utilizing an amphetamine compound. This method can include determining memory consolidation before, during, and/or after administering the amphetamine compound.
Career Highlights
Throughout his career, Kjesten A Wiig has worked with various companies, including Cognition Pharmaceuticals LLC and Sention, Inc. His work in these organizations has allowed him to further his research and development in cognitive health.
Collaborations
Wiig has collaborated with notable individuals in his field, including Mel H Epstein and Randall L Carpenter. These collaborations have contributed to the advancement of his innovative methods and research.
Conclusion
Kjesten A Wiig's contributions to cognitive health through his patents and collaborations highlight his dedication to improving the lives of individuals affected by cognitive impairments. His innovative approaches continue to pave the way for advancements in treatment options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile